Medicine Development Needs Radical Reform: Commentary
Journal Title: UNKNOWN - Year 2017, Vol 7, Issue 4
Abstract
Medicines are a vital and an expensive component of health care. The present situation with regard both to the development and licensing of medicines, and to their pricing and supply are in a state that damages the provision of healthcare particularly in poorer countries but also throughout the world. There is surprisingly widespread agreement that the whole process requires radical reform. The political will to bring this about has, however, so far not been sufficient to effect more than rather minor changes
Authors and Affiliations
Peter J. Lachmann
Keywords
Related Articles
- EP ID EP386724
- DOI 10.4172/2167-0870.1000320
- Views 47
- Downloads 0
Feasibility Study of Bolus 5-Fluorouracil+L-Leucovorin as Salvage Line Chemotherapy for Oral Fluorouracil-Resistant Unresectable Gastric Cancer: Hokkaido Gastrointestinal Cancer Study Group Study HGCSG1502
In November 2015 we began a feasibility study of salvage line chemotherapy with 5-fluorouracil and l-leucovorin given in an intravenous bolus once weekly followed by a 2-week rest period within a 8-week cycle in patients...
Pre-Senile Cataract in Diabetic Patients: Prevalence and Early Diagnosis
Hypothesis: Since cataract is more prevalent in the diabetic population, the authors compared the findings of the gold standard Lens Opacity Classification System III (LOCSIII) with the Scheimpflug objective measures in...
Hierarchical Agglomerative Cluster Analysis as a Trial Method Revealing Developmental Coordination Disorder (DCD) Subtypes
Background: There is increasing evidence that children with DCD have been classified into distinguishable ‘subtypes’ mainly based on perceptual-motor, fine and gross motor skills. Previous research efforts define and des...
Erythroderma Due to the Association of Pegylated Interferon Alpha-2a and Ribavirin
The dermatological adverse effects due to the association of interferon Alpha and ribavirin in patients treated for hepatitis C are becoming more frequent but little is known about them. Such adverse effects range from e...
Design of a Multicenter, Randomized, Open Label, Parallel Group Study to Evaluate the Efficacy of Loxoprofen on Acute-Phase Reactions in Japanese Primary Osteoporosis Patients Treated with Zoledronic Acid
Treatment of osteoporosis with once-yearly zoledronic acid was approved in September 2016 in Japan. Like other bisphosphonates, zoledronic acid causes acute-phase responses (APRs), which are more severe in Asian populati...